Psycheceutical Bioscience

Psycheceutical Bioscience is a private, pre-revenue biotech founded in 2019, pioneering a novel topical drug delivery system for psychedelic medicines. The company's NeuroDirect™ technology, applied at the back of the neck, is designed to deliver compounds like ketamine directly to neural targets, aiming to reduce systemic side effects such as hallucinations and improve dosing control. Its lead program, NeuroDirect™ Ketamine for PTSD, is in Phase 1 clinical trials, positioning the company at the intersection of the growing psychedelics therapeutics and advanced drug delivery markets. The company is headquartered in Miami, Florida.

NeuroDirect™ non-systemic delivery technology: a patented topical formulation applied at the back of the neck designed to deliver neuro-active compounds directly into peripheral nerve tissue, bypassing systemic circulation and the GI tract to reduce side effects.

Competes with numerous biotechs developing oral/injectable psychedelics (e.g., Compass Pathways, MindMed) and drug delivery companies. Differentiation hinges on proving NeuroDirect™ offers superior safety/efficacy by minimizing psychedelic effects.